MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.
Mazdutide acetate is a long-acting glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. Mazdutide acetate stimulates insulin secretion from mouse pancreatic islets, and can be used in studies of obesity and type 2 diabetes (T2D).
MAZ51 is an indolinone that blocks the ligand-induced autophosphorylation of VEGFR-3 by VEGF-C. It was shown to inhibit proliferation and induce apoptosis of tumor cell lines.
Marinobufagenin (marinobufagin) is a cardiotonic bufadienolide steroid secreted by the toad Bufo rubescens and other related species such as Bufo marinus. It is a vasoconstrictor with effects similar to digitalis.
Manzamine A is an alkaloid in the class of β-carboline isolated from the marine sponges. It acts as an inhibitor of glycogen synthase kinase 3β (GSK3β). It exhibits inhibitory effects against growth of the rodent malaria parasite Plasmodium berghei in vivo.
Malvidin-3-O-arabinoside chloride is found in the fruits of Vaccinium myrtillus, it shows antioxidant activity.It has potential preventive effect in colorectal diseases.
MAK683 is an inhibitor of embryonic ectoderm development protein (EED) with potential antineoplastic activity. MAK683 binds to the domain of EED that interacts with trimethylated lysine 27 on histone 3 (H3K27me3), leading to a conformational change in the EED H3K27me3-binding pocket and preventing the interaction of EED with the histone methyltransferase enhancer zeste homolog 2 (EZH2). MAK683 is undergoing phase II clinical trials for the identification of antitumor activity.
Magnoflorine chloride is an aporphine alkaloid found in flowers of Magnolia liliiflora Desr. It exhibits antioxidant, α-tyrosinase inhibitory and anti-inflammationary activities.
Magnesium aluminosilicate has long been used in the formulation of tablets, ointments and creams. It is used as a suspension and stabilizer alone or in combination with other suspension agents in oral and topical formulations. In tablets, it is used as a binder and disintegrating agent in conventional or sustained-release preparations.
It is a novel Trinder's reagent used as a water-soluble reagent for the determination of hydrogen peroxide by enzyme spectrophotometry, and is widely used in diagnostic detection and biochemical test.
M344 is a potent HDAC inhibitor, which can also induce expression of the pro-apoptotic genes, Puma and Bax, together with the morphological features of apoptosis, in MCF-7 cells.
L-α-phosphatidylcholine (soybean, hydrogenated) is a saturated phospholipid used in liposomal drug delivery formulations. It is also known to increase the solubility and bioavailability of hydrophobic drugs.
L-α-Aspartyl-D-phenylalanine methyl ester, a dipeptide compound, bears promise in the biomedical sector for its potential inhibitory impact on angiotensin converting enzyme (ACE), thus potentially reducing blood pressure levels. It has also shown potential in the treatment of hypertensive, cardiac failure, and other cardiovascular conditions. The study of its properties continues to generate interest and attention from academia and the scientific community.
Lys05, a water-soluble salt of Lys01, is a selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively, resulting in sustained inhibition of autophagy and tumor growth.
Lycobetaine is a remarkable biomedical innovation engineered to efficaciously study intricate cardiovascular maladies. Harnessing the invaluable attributes derived from bountiful bionatural origins, Lycobetaine proficiently merges indispensable nutritive constituents with potent antioxidants.
LY-900009 is a small-molecule inhibitor of Notch signalling with IC50 value of 0.27 nM via selective inhibition of the γ-secretase protein. LY-900009 was developed as a candidate therapeutic drug against AD (IDENTITY trial), which failed in phase III trials.
LY-411575, also known as LSN-411575, is a potent, cell-permeable γ-secretase inhibitor (IC50 = 0.078 nM/0.082 nM in membrane-assay/in cell-basedγ-secretase assays) and also inhibits Notch clevage (IC50 = 0.39 nM).
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3.
LY364947 is a selective inhibitor of TGF-β type-I receptor with potential anticancer activity. LY364947 inhibits TGF-β-dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3).
LY2795050, a κ-opioid Receptor antagonist, has been found to be effective in imaging KOR behaving as a PET tracer. IC50: 0.72 nM and 25.8 nM for κ-opioid Receptor and κ-opioid.
LY2784544 is a potent and selective JAK2 inhibitor (IC50 = 3 nM), and exhibits less potency against JAK3 (IC50 =48 nM). LY2784544 effectively inhibits JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50 = 20 and 55 nM, respectively). It reduces JAK2V617F tumor cell burden with no effect on erythroid progenitor cells.
LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. It was developed by Eli Lilly and Company and in clinic phase 1 trials with no progress.
LY-2456302, also called as CERC-501, is a potent, highly selective and centrally-penetrant kappa opioid receptor antagonist (Ki = 0.807 nM) with favorable pharmacokinetic and pharmacodynamic properties to evaluate the role of KOR in preclinical models of alcoholism.
LY2228820 dimesylate is the salt form of LY2228820, a tri-substituted imidazole derivative and p38α and β MAPK inhibitor. LY2228820 inhibits tumor growth in various cancer models.
LY2109761 is a novel inhibitor of TGF-β receptor type I/type II kinases (IC50 = 69 nM), displaying antitumor activity. In vivo study demonstrated that LY2109761, in combination with gemcitabine, significantly reduced the tumor burden, prolonged survival, and reduced spontaneous abdominal metastases.
L-Xylulose, an organic sugar alcohol, finds significant utility within the dynamic biomedicine sector as a crucial carbohydrate source and an intermediary compound in the synthesis of pharmaceuticals and biochemicals.
